You are here

Celgene

Celgene shareholders are parsing blurry photos in search of a payday

Celgene shareholders are parsing blurry photos in search of a payday

Stat

Bristol-Myers Squibb

Flag link:

Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity

Bristol Myers’ Hirawat on Pipeline Progress, Clinical Trial Diversity

Xconomy

Bristol-Myers Squibb

clinical trials

clinical trial diversity

Flag link:

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

Congressional investigation reveals Celgene, Teva plotted to keep drug prices high

RAPS.org

Teva Pharmaceutical

Flag link:

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

Fierce Pharma

Bristol-Myers Squibb

Teva Pharmaceutical

Flag link:

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

Fierce Biotech

Bristol-Myers Squibb

priority review

Flag link:

Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms

Ex-Celgene exec steers his biotech startup to Hong Kong IPO as potential cancer drug launch looms

Endpoints

Flag link:

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

Fierce Pharma

Flag link:

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals

Fierce Pharma

Flag link:

After Celgene deal, BMS shoots up pharma market cap rankings

After Celgene deal, BMS shoots up pharma market cap rankings

Pharmaforum

Bristol-Myers Squibb

Flag link:

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study

BioSpace

triple negative breast cancer

clinical trials

Flag link:

Bristol's Celgene merger sees it bounce Jounce drug pact

Bristol's Celgene merger sees it bounce Jounce drug pact

Fierce Biotech

Bristol-Myers Squibb

Jounce Therapeutics

immuno-oncology

Flag link:

Bristol Myers Squibb's Zeposia launches into crowded MS market

Bristol Myers Squibb's Zeposia launches into crowded MS market

Fierce Pharma

Bristol-Myers Squibb

multiple sclerosis

Flag link:

Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

Motley Fool

Bristol-Myers Squibb

Flag link:

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Fierce Pharma

Flag link:

CHMP backs BMS’ first-in-class anemia drug Reblozyl

CHMP backs BMS’ first-in-class anemia drug Reblozyl

Pharmaforum

Bristol-Myers Squibb

Flag link:

Amgen's anti-inflammatory Otezla makes its foray into COVID-19

Amgen's anti-inflammatory Otezla makes its foray into COVID-19

Fierce Pharma

Flag link:

Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise

Bristol Myers to CEO Caforio: Good job on Celgene so far, but you'll have to work for your raise

Fierce Pharma

Bristol-Myers Squibb

Giovanni Caforio

Flag link:

Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T

Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T

Endpoints

Bristol-Meyers Squibb

Flag link:

FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch

FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch

Xconomy

Bristol-Meyers Squibb

mutliple sclerosis

Flag link:

Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy

Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy

Endpoints

Bristol-Myers Squibb

clinical trials

Multiple Myeloma

Flag link:

Pages